期刊文献+

加味黄芪桂枝五物汤防治希罗达相关性手足综合征的临床观察 被引量:24

Clinial Study of Jiawei Huangqi Guizhi Wuwu Decoction on Prevention of Hand-foot Syndrome Caused by Xeloda
下载PDF
导出
摘要 目的:观察中药加味黄芪桂枝五物汤防治希罗达相关性手足综合征的临床疗效。方法:53例患者随机分为治疗组29例和对照组24例,治疗组在化疗同时口服加味黄芪桂枝五物汤,每日1剂,对照组常规化疗,观察2组手足综合征的发生情况。结果:治疗组手足综合征的发生率34.5%,对照组手足综合征的发生率58.3%,2组比较差异有显著性(P<0.05)。结论:加味黄芪桂枝五物汤对防治希罗达相关性手足综合征有一定疗效。 Objective : To investigate the effects of Jiawei Huangqi Guizhi Wuwu Decoction on prevention of hand - foot syndrome caused by xeloda. Methods: 53 patients were divided randomly into the treatement group and the control group. The treatement group takes chemotherapy plus Jiawei Huangqi Guizhi Wuwu Decoction, one dose everyday. The control group takes chemotherapy alone. Results : 34.5% of patients suffered from hand - foot syndrome in treatment group and 58.3% in control group, 2 groups of comparisons differences have signigicance ( P 〈 0. 05 ). Conclusion : Jiawei Huangqi Guizhi Wuwu Decoction could prevent and treat hand - foot syndrome caused by xeloda.
出处 《辽宁中医杂志》 CAS 北大核心 2007年第6期783-784,共2页 Liaoning Journal of Traditional Chinese Medicine
关键词 希罗达 手足综合征 黄芪桂枝五物汤 中医药疗法 xeloda hand- foot syndrome Huangqi Guizhi Wuwu decoction TCM therapeutics
  • 相关文献

参考文献5

  • 1Reichardt P,Von Mackwitz G,Thuss-Patience PC,et al.Multicenter phase Ⅱ study of oral caoecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy[J].Ann Oncol,2003,14:1227-1233
  • 2Abushull aih S,Saad ED,Muusell M,et al.Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine:a single-institution experience[J].Cancer Invest,2002,20:3-10
  • 3刘冬耕,管忠震,宋三泰,刘晓晴,冯奉仪,张频,董梅,许立功,印季良,于世英,陈元.希罗达对晚期乳腺癌患者二线化疗临床研究[J].癌症,2001,20(12):1405-1407. 被引量:35
  • 4王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量:57
  • 5Lin E,Morris JS,Ayers GD.Effect of celecoxid on capecitabine-induced hand-foot syndrome and antitumor[ J ].Oncology,2002,16:31-37

二级参考文献9

  • 1[1]Budman DR, Meropol NJ, Reiger B, et al. Preliminary studies of a novel fluoropyrimidine carbamate: Capecitabine [J]. J Clin Oncol, 1998, 16: 1795-1802.
  • 2[2]Mackean MJ, Planting AS, Twelves C, et al. A Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer [J]. J Clin Oncol, 1998, 16: 2977-2985.
  • 3Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol, 1999,17:485-493.
  • 4Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002,86:1367-1372.
  • 5Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase Ⅱ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 2001,92:1759-1768.
  • 6Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase Ⅱ study of oral capecitabine (Xeloda('')) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol, 2003,14:1227-1233.
  • 7Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecita-bine: a single-institution experience. Cancer Invest, 2002,20:3-10.
  • 8Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology, 2002,16:31-37.
  • 9McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol, 1996,41:425-427.

共引文献89

同被引文献253

引证文献24

二级引证文献129

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部